Jennings A, Rutherford M, Lambert P
Stat Med. 2025; 44(6):e70035.
PMID: 40059376
PMC: 11891414.
DOI: 10.1002/sim.70035.
Liu L, Wang L, Ding Y, Zhang Q, Shu Y
BMJ Open. 2025; 15(3):e094804.
PMID: 40050065
PMC: 11887288.
DOI: 10.1136/bmjopen-2024-094804.
Boyle P, Wang T, Mottola G, Stewart C, Wilson R, Bennett D
Alzheimers Dement. 2025; 21(3):e14544.
PMID: 40042433
PMC: 11881619.
DOI: 10.1002/alz.14544.
Hao J, Alizadeh B, Postma M, Touw D, Bakker S, de Jong L
PLoS One. 2025; 20(2):e0319022.
PMID: 40014627
PMC: 11867398.
DOI: 10.1371/journal.pone.0319022.
Jackson D, Ran D, Zhang F, Ouwens M, Druker V, Sweeting M
Pharm Stat. 2025; 24(1):e2462.
PMID: 39905716
PMC: 11794985.
DOI: 10.1002/pst.2462.
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.
Fawsitt C, Pan J, Orishaba P, Jackson C, Thom H
BMC Med Res Methodol. 2025; 25(1):26.
PMID: 39885377
PMC: 11780865.
DOI: 10.1186/s12874-025-02480-x.
Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.
Lang Y, Chai Q, Lin Y, Wu B, Liu X
Front Pharmacol. 2025; 15:1495082.
PMID: 39881877
PMC: 11774713.
DOI: 10.3389/fphar.2024.1495082.
The role of VANGL2 in glioma oncogenesis and progression: insights into expression profiles and prognostic relevance.
Zhao M, Chen S
Front Oncol. 2025; 14:1527226.
PMID: 39871948
PMC: 11770008.
DOI: 10.3389/fonc.2024.1527226.
Case-Base Neural Network: Survival analysis with time-varying, higher-order interactions.
Islam J, Turgeon M, Sladek R, Bhatnagar S
Mach Learn Appl. 2025; 16.
PMID: 39802089
PMC: 11720922.
DOI: 10.1016/j.mlwa.2024.100535.
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer.
Ziegler D, Parashar K, Leal-Esteban L, Lopez-Alcala J, Castro W, Zanou N
Nat Commun. 2025; 16(1):541.
PMID: 39788939
PMC: 11718081.
DOI: 10.1038/s41467-024-55605-z.
Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2024; 24(8):1-306.
PMID: 39698418
PMC: 11650780.
A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment.
Chen E, Dickman P, Clements M
Pharmacoeconomics. 2024; 43(3):297-310.
PMID: 39586963
PMC: 11825556.
DOI: 10.1007/s40273-024-01457-w.
CRISPR-Cas9-mediated enhancement of Beauveria bassiana virulence with overproduction of oosporein.
Mascarin G, Shrestha S, Cortes M, Ramirez J, Dunlap C, Coleman J
Fungal Biol Biotechnol. 2024; 11(1):21.
PMID: 39574174
PMC: 11583550.
DOI: 10.1186/s40694-024-00190-5.
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Archer K, Fu H, Mrozek K, Nicolet D, Mims A, Uy G
Innovation (Camb). 2024; 5(6):100719.
PMID: 39529956
PMC: 11551470.
DOI: 10.1016/j.xinn.2024.100719.
Association of lifetime lactation and characteristics of menopause: a longitudinal cohort study.
Scime N, Huang B, Brockway M, Brown H, Brennand E
BMC Public Health. 2024; 24(1):3112.
PMID: 39529030
PMC: 11552320.
DOI: 10.1186/s12889-024-20508-7.
iSubGen generates integrative disease subtypes by pairwise similarity assessment.
Fox N, Tian M, Markowitz A, Haider S, Li C, Boutros P
Cell Rep Methods. 2024; 4(11):100884.
PMID: 39447572
PMC: 11705582.
DOI: 10.1016/j.crmeth.2024.100884.
Assessment of NSCLC disease burden: A survival model-based meta-analysis study.
Kudryashova N, Shulgin B, Katuninks N, Kulesh V, Helmlinger G, Zhudenkov K
Comput Struct Biotechnol J. 2024; 24:611-621.
PMID: 39417203
PMC: 11480949.
DOI: 10.1016/j.csbj.2024.09.012.
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
Weber J, Middleton M, Yates G, Sharpe D, Kurt M, Lobo M
J Clin Oncol. 2024; 43(8):929-937.
PMID: 39378385
PMC: 11895827.
DOI: 10.1200/JCO.24.00237.
MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.
Llewellyn A, Phung T, Soares M, Shepherd L, Glynn D, Harden M
Health Technol Assess. 2024; 28(61):1-310.
PMID: 39367754
PMC: 11472214.
DOI: 10.3310/PLFG4210.
A biological age based on common clinical markers predicts health trajectory and mortality risk in dogs.
Herzig S, Zollinger A, Texari L, Holzwarth J, Middleton R, Pan Y
Geroscience. 2024; 47(1):45-59.
PMID: 39349737
PMC: 11872834.
DOI: 10.1007/s11357-024-01352-4.